These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 19195322)

  • 41. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
    De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
    J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
    Askarieh G; Alsiö A; Pugnale P; Negro F; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Norkrans G; Westin J; Söderholm J; Hellstrand K; Lagging M;
    Hepatology; 2010 May; 51(5):1523-30. PubMed ID: 20186843
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
    Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
    J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.
    Arnaud C; Pradat P; Spaziante M; Berthillon P; Maynard M; Taliani G; Chemin I; Trépo C; Petit MA
    Antivir Ther; 2013; 18(8):1027-32. PubMed ID: 23948510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.
    Rivero-Juarez A; Mira JA; Camacho A; Neukam K; Perez-Camacho I; Caruz A; Macias J; Torre-Cisneros J; Pineda JA; Rivero A
    Infection; 2013 Feb; 41(1):21-6. PubMed ID: 23065463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients.
    Cesari M; Caramma I; Antinori S; Adorni F; Galli M; Milazzo L
    HIV Med; 2009 Oct; 10(9):580-5. PubMed ID: 19785667
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.
    Cacoub P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Pol S; Halfon P
    Antivir Ther; 2009; 14(6):839-45. PubMed ID: 19812446
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV.
    Odolini S; Amadasi S; Cerini C; Giralda M; Nasta P; Castelli F
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S4. PubMed ID: 25236496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
    Halfon P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Cacoub P
    Antivir Ther; 2009; 14(2):211-9. PubMed ID: 19430096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
    Labarga P; Fernández-Montero JV; de Mendoza C; Barreiro P; Soriano V
    Antivir Ther; 2015; 20(1):65-72. PubMed ID: 25105286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.
    Mascia C; Lichtner M; Zuccalà P; Vita S; Tieghi T; Marocco R; Savinelli S; Rossi R; Iannetta M; Campagna M; Schiavone F; Mengoni F; Russo G; Mastroianni CM; Vullo V
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):644-655. PubMed ID: 28578937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus.
    Ryan P; Resino S; Miralles P; Cosín J; López JC; Moreno S; Catalán P; Ramírez M; Gutiérrez I; Berenguer J
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):176-81. PubMed ID: 20577091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1.
    Vargas A; Berenguer J; Ryan P; Catalán P; López JC; Cosín J; Miralles P; Resino S
    J Acquir Immune Defic Syndr; 2010 Jun; 54(2):219-20. PubMed ID: 20505475
    [No Abstract]   [Full Text] [Related]  

  • 56. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
    Dominguez S; Ghosn J; Cassard B; Melica G; Poizot-Martin I; Solas C; Lascaux AS; Bouvier-Alias M; Katlama C; Lévy Y; Peytavin G
    J Antimicrob Chemother; 2012 Jun; 67(6):1449-52. PubMed ID: 22396433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
    Crisan D; Grigorescu MD; Radu C; Suciu A; Grigorescu M
    Indian J Med Res; 2017 Apr; 145(4):543-550. PubMed ID: 28862188
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus.
    Lee S; Varano J; Flexman JP; Cheng W; Watson MW; Rossi E; Adams LA; Bulsara M; Price P
    Dis Markers; 2010; 28(5):273-80. PubMed ID: 20592450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon.
    Amaral Ido S; Móia Lde J; Barbosa MS; Demachki S; Araújo MT; Soares Mdo C
    Rev Soc Bras Med Trop; 2013; 46(1):20-3. PubMed ID: 23563820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
    Stasi C; Piluso A; Arena U; Salomoni E; Montalto P; Monti M; Boldrini B; Corti G; Marra F; Laffi G; Milani S; Zignego AL
    World J Gastroenterol; 2015 Mar; 21(10):3013-9. PubMed ID: 25780300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.